HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DP-VPA

for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Valerates: 135
      - Pentanoic Acids: 1
        Valproic Acid: 9766
        DP-VPA: 5
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Valerates: 135
      - Pentanoic Acids: 1
        Valproic Acid: 9766
        DP-VPA: 5

Experts

1.	Cao, Guoying: 1 article (07/2019)
2.	Chen, Yuancheng: 1 article (07/2019)
3.	Fan, Yaxin: 1 article (07/2019)
4.	Guo, Beining: 1 article (07/2019)
5.	Li, Yi: 1 article (07/2019)
6.	Yu, Jicheng: 1 article (07/2019)
7.	Zhan, Huizhong: 1 article (07/2019)
8.	Zhang, Jing: 1 article (07/2019)
9.	Bialer, Meir: 1 article (04/2003)
10.	Isoherranen, Nina: 1 article (04/2003)

Related Diseases

1.	Epilepsy (Aura) 07/01/2023 - "The present study explored the pharmacokinetics (PK) and exposure safety of DP-VPA to provide a basis for future studies exploring the safe dosage and therapeutic strategies for epilepsy. " 06/01/2002 - "In the case of DP-VPA, the pathological epilepsy process activates it on demand [342433]. " 04/01/2003 - "At present there are three compounds in clinical trials in patients with epilepsy that can be regarded as second-generation VPA: valproyl glycinamide, 3-methylbutanamide or isovaleramide and SPD421 (DP-VPA). " 07/01/2023 - "Phospholipid-valproic acid (DP-VPA)is a prodrug for treating epilepsy. " 07/01/2019 - "DP-VPA is a phospholipid prodrug of valproic acid (VPA) that is developed as a potential treatment for epilepsy. "
2.	Status Epilepticus (Complex Partial Status Epilepticus) 06/01/2002 - "Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine [242649], [385958]; the drug is also being developed for bipolar disorder and migraine prophylaxis [385862]. "
3.	Seizures (Absence Seizure) 06/01/2002 - "Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine [242649], [385958]; the drug is also being developed for bipolar disorder and migraine prophylaxis [385862]. "
4.	Migraine Disorders (Migraine) 06/01/2002 - "Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine [242649], [385958]; the drug is also being developed for bipolar disorder and migraine prophylaxis [385862]. "
5.	Bipolar Disorder (Manic Depressive Psychosis) 06/01/2002 - "Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine [242649], [385958]; the drug is also being developed for bipolar disorder and migraine prophylaxis [385862]. "

Related Drugs and Biologics

1.	Levetiracetam (Keppra)
2.	Pregabalin (Lyrica)
3.	AWD 131-138
4.	soretolide
5.	ganaxolone
6.	ezogabine (retigabine)
7.	rufinamide
8.	remacemide
9.	losigame (A033)
10.	isovaleramide